Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOE-105 Phase IIa open-label study in male adults and adolescents with Tourette syndrome
2021-004424-15Phase 2Completed
- Sponsor
- Noema Pharma
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemlapodect in Tourette syndrome (TS), sponsored by Noema Pharma. Primary endpoint: Tourette Syndrome Clinical Global Impression of Change response at week 12 or post treatment. Started Oct 2021; status: completed.
02
Drugs
gemlapodect
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2021-004424-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004424-15.